These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 16335673)

  • 1. [Assessment of pro- and antiangiogenic factors blood serum concentrations in patients with hormonal inactive adrenal tumors].
    Korzeniewska M; Kołomecki K; Stepień H; Naze M; Stepień T; Kuzdak K
    Endokrynol Pol; 2005; 56(1):39-44. PubMed ID: 16335673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The usefulness of determining the serum concentrations of vascular endothelial growth factor (VEGF) and its soluble receptor type 2 (sVEGF-2) in the differential diagnosis of adrenal incidentalomas.
    Foltyn W; Strzelczyk J; Marek B; Kajdaniuk D; Siemińska L; Rosiek V; Kos-Kudła B
    Endokrynol Pol; 2012; 63(1):22-8. PubMed ID: 22378094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus.
    Robak E; Sysa-Jedrzejewska A; Robak T
    Mediators Inflamm; 2003 Oct; 12(5):293-8. PubMed ID: 14760936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical usefulness of assessing VEGF and soluble receptors sVEGFR-1 and sVEGFR-2 in women with breast cancer.
    Thielemann A; Baszczuk A; Kopczyński Z; Kopczyński P; Grodecka-Gazdecka S
    Ann Agric Environ Med; 2013; 20(2):293-7. PubMed ID: 23772579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selected angiogenic factors in plasma of patients with lower limb symptomatic peripheral arterial disease: preliminary report.
    Wieczór R; Gadomska G; Góralczyk B; Stankowska K; Budzyński J; Fabisiak J; Suppan K; Pulkowski G; Rość D
    Int Angiol; 2015 Dec; 34(6):545-51. PubMed ID: 25394959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overweight and obesity versus concentrations of VEGF-A, sVEGFR-1, and sVEGFR-2 in plasma of patients with lower limb chronic ischemia.
    Wieczór R; Wieczór AM; Gadomska G; Stankowska K; Fabisiak J; Suppan K; Pulkowski G; Budzyński J; Rość D
    J Zhejiang Univ Sci B; 2016 Nov.; 17(11):842-849. PubMed ID: 27819131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of type 2 diabetes on the plasma levels of vascular endothelial growth factor and its soluble receptors type 1 and type 2 in patients with peripheral arterial disease.
    Wieczór R; Gadomska G; Ruszkowska-Ciastek B; Stankowska K; Budzyński J; Fabisiak J; Suppan K; Pulkowski G; Rość D
    J Zhejiang Univ Sci B; 2015 Nov; 16(11):948-56. PubMed ID: 26537213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia.
    Wierzbowska A; Robak T; Wrzesień-Kuś A; Krawczyńska A; Lech-Marańda E; Urbańska-Ryś H
    Eur Cytokine Netw; 2003; 14(3):149-53. PubMed ID: 14656688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral blood concentrations of vascular endothelial growth factor and its soluble receptors (R1 and R2) in patients with adrenal cortex tumours treated by surgery.
    Jurczyńska J; Stepień T; Lawnicka H; Stepień H; Krupiński R; Kołomecki K; Kuzdak K; Komorowski J
    Endokrynol Pol; 2009; 60(1):9-13. PubMed ID: 19224499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer.
    Chang YT; Chang MC; Wei SC; Tien YW; Hsu C; Liang PC; Tsao PN; Jan IS; Wong JM
    Pancreas; 2008 Aug; 37(2):145-50. PubMed ID: 18665074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum inhibin pro-αC is a tumor marker for adrenocortical carcinomas.
    Hofland J; Feelders RA; van der Wal R; Kerstens MN; Haak HR; de Herder WW; de Jong FH
    Eur J Endocrinol; 2012 Feb; 166(2):281-9. PubMed ID: 22127493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGF-A, sVEGFR-1, and sVEGFR-2 in BCR-ABL negative myeloproliferative neoplasms.
    Gadomska G; Stankowska K; Boinska J; Ślusarz R; Tylicka M; Michalska M; Jachalska A; Rość D
    Medicina (Kaunas); 2017; 53(1):34-39. PubMed ID: 28237691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC.
    Jantus-Lewintre E; Sanmartín E; Sirera R; Blasco A; Sanchez JJ; Tarón M; Rosell R; Camps C
    Lung Cancer; 2011 Nov; 74(2):326-31. PubMed ID: 21481963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy.
    Matsunaga N; Chikaraishi Y; Izuta H; Ogata N; Shimazawa M; Matsumura M; Hara H
    Ophthalmology; 2008 Nov; 115(11):1916-22. PubMed ID: 18718666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced serum vascular endothelial growth factor receptor-2 (sVEGFR-2) and sVEGFR-1 levels in gastric cancer patients.
    Kikuchi S; Obata Y; Yagyu K; Lin Y; Nakajima T; Kobayashi O; Kikuichi M; Ushijima R; Kurosawa M; Ueda J
    Cancer Sci; 2011 Apr; 102(4):866-9. PubMed ID: 21219538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer.
    Perroud HA; Rico MJ; Alasino CM; Pezzotto SM; Rozados VR; Scharovsky OG
    Indian J Cancer; 2013; 50(2):115-21. PubMed ID: 23979202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship of serum VEGF and sVEGFR-1 levels with vascular involvement in patients with Behçet's disease.
    Sertoglu E; Omma A; Yucel C; Colak S; Sandıkcı SC; Ozgurtas T
    Scand J Clin Lab Invest; 2018 Oct; 78(6):443-449. PubMed ID: 30015524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients.
    Ustuner Z; Saip P; Yasasever V; Vural B; Yazar A; Bal C; Ozturk B; Ozbek U; Topuz E
    Med Oncol; 2008; 25(4):394-9. PubMed ID: 18317954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGF and its soluble receptor VEGFR-2 in hypertensive disorders during pregnancy: the Indian scenario.
    Rath G; Tripathi R
    J Hum Hypertens; 2012 Mar; 26(3):196-204. PubMed ID: 21412269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours.
    Kolomecki K; Stepien H; Bartos M; Kuzdak K
    Endocr Regul; 2001 Mar; 35(1):9-16. PubMed ID: 11308991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.